NOTRELOAD AI
  • NOTRELOAD AI
  • myNOTRELOAD
  • One-Time License
  • Invest ↗
  • XY Feed
  • Push Notifications
Sign in Subscribe

Incannex IHL-42X Secures FDA Fast Track for OSA Treatment

Incannex's oral drug (IHL-42X) for serious sleep apnea (OSA) got FDA Fast Track status to speed up its development and potential approval.

Incannex IHL-42X Secures FDA Fast Track for OSA Treatment
Credit: Incannex/Nasdaq
Already have an account? Sign in.
12/03/2025 · 2:40 PM
IXHL
/ Read more

Feed↓

Apple Developing Autonomous AI Agent for Apps, Browsing, and Coding
Featured/ 11/19/2026 · 5:31 PM

Apple Developing Autonomous AI Agent for Apps, Browsing, and Coding

Apple is developing a general-purpose AI agent that can browse the web, control apps, and write code, with a possible launch by late 2027.

/ Subscriber only
William Blair Upgrades Pyxis Oncology to Outperform on Strong Phase 1 Data for MICVO in Head and Neck Cancer
11/19/2026 · 5:16 PM

William Blair Upgrades Pyxis Oncology to Outperform on Strong Phase 1 Data for MICVO in Head and Neck Cancer

Blair raised its rating on PYXS following updated Phase 1 results for MICVO, citing 39% response rate, 9.2-month durability, and Phase 3 plans.

/ Subscriber only
Celldex Halts Barzolvolimab Development for Atopic Dermatitis After Phase 2 Miss
11/19/2026 · 5:05 PM

Celldex Halts Barzolvolimab Development for Atopic Dermatitis After Phase 2 Miss

Celldex’s Phase 2 trial of barzolvolimab in atopic dermatitis missed key efficacy goals. The company is ending development in eczema while advancing the drug in other indications.

/ Subscriber only
Explore
  • NOTRELOAD AI
  • myNOTRELOAD
  • One-Time License
  • Invest ↗
  • XY Feed
  • Push Notifications
More
  • Sign up
  • Sign in
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Terms/Privacy
  • UP↑
Get alerts

Be the first to know when deals break, stocks move, or biotech headlines hit.

Email address Subscribe
DON'T FALL BEHIND. ©2026
For informational purposes only. Not financial advice.
NOTRELOAD AI